Antiplatelet aggregant agents and thrombolytic compounds in myocardial infarction: current status.
D000925:Anticoagulants / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D001779:Blood Coagulation Factors; D003374:Coumarins / Q000627:therapeutic use; D003911:Dextrans / Q000627:therapeutic use; D004176:Dipyridamole / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D010973:Platelet Adhesiveness / Q000187:drug effects*; D011453:Prostaglandins / Q000627:therapeutic use; D013300:Streptokinase / Q000627:therapeutic use; D013923:Thromboembolism / Q000517:prevention & control
D000925:Anticoagulants; D001779:Blood Coagulation Factors; D003374:Coumarins; D003911:Dextrans; D005343:Fibrinolytic Agents; D011453:Prostaglandins; D004176:Dipyridamole; D006493:Heparin; D013300:Streptokinase; D001241:Aspirin